Edesa Biotech, Inc. Annual Report - How They Did This Year

Hey there, fellow investor! Let's take a look at what Edesa Biotech has been up to this past year, ending September 30, 2025, and what's happened since.

Keeping the Lights On: How They're Funding Their Work

Edesa was busy securing capital and has been quite active in raising money through various channels:

• Selling Shares: They issued different types of preferred stock (like Series A1 and Series B1) and warrants. Some of these shares and warrants were issued to key people, including their CEO.
• "At-The-Market" (ATM) Offerings: They've set up agreements to sell shares directly into the stock market over time. They had one such agreement in early October 2024 and another related event in October 2025.
• Loans: Edesa also had a revolving credit facility available throughout the year. They also participated in the Canada Emergency Business Account Program (CEBA), a government loan program.
• Employee Compensation: They're using Restricted Stock Units (RSUs) and stock options.

These activities show that Edesa is actively managing its finances to support its operations and research.

What They're Working On: Developing New Medicines

On the business development front, Edesa is focused on expanding its pipeline:

• Licensing Deals: They've entered into agreements to acquire global rights for certain pharmaceutical products, bringing in new potential treatments to develop.
• "The Constructs" Drug Substance: The company is actively working on something referred to as "The Constructs" drug substance, which is a key part of their research and development efforts for new therapies.

Looking Ahead (and Back at Taxes)

The company's financial records mention various tax years for both domestic and foreign operations, often related to tax loss carryforwards. This indicates that Edesa has accumulated losses from its research and development efforts, which can be used to reduce future tax bills if they become profitable.